- Home
- SABS vs EDSA Comparison
SABS vs EDSA Comparison
Compare SABS & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- EDSA
- Stock Information
- Founded
- SABS 2014
- EDSA 2015
- Country
- SABS United States
- EDSA Canada
- Employees
- SABS N/A
- EDSA N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- SABS Health Care
- EDSA Health Care
- Exchange
- SABS Nasdaq
- EDSA Nasdaq
- Market Cap
- SABS 15.8M
- EDSA 18.6M
- IPO Year
- SABS N/A
- EDSA N/A
- Fundamental
- Price
- SABS $2.35
- EDSA N/A
- Analyst Decision
- SABS Strong Buy
- EDSA Strong Buy
- Analyst Count
- SABS 4
- EDSA 2
- Target Price
- SABS $9.50
- EDSA $13.00
- AVG Volume (30 Days)
- SABS 427.8K
- EDSA 135.8K
- Earning Date
- SABS 11-05-2025
- EDSA 08-08-2025
- Dividend Yield
- SABS N/A
- EDSA N/A
- EPS Growth
- SABS N/A
- EDSA N/A
- EPS
- SABS N/A
- EDSA N/A
- Revenue
- SABS $114,698.00
- EDSA N/A
- Revenue This Year
- SABS N/A
- EDSA N/A
- Revenue Next Year
- SABS N/A
- EDSA N/A
- P/E Ratio
- SABS N/A
- EDSA N/A
- Revenue Growth
- SABS N/A
- EDSA N/A
- 52 Week Low
- SABS $1.00
- EDSA $1.55
- 52 Week High
- SABS $6.60
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- SABS 54.67
- EDSA 51.07
- Support Level
- SABS $2.20
- EDSA $2.42
- Resistance Level
- SABS $2.60
- EDSA $2.90
- Average True Range (ATR)
- SABS 0.19
- EDSA 0.22
- MACD
- SABS 0.02
- EDSA -0.02
- Stochastic Oscillator
- SABS 68.00
- EDSA 39.70
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.